BioCentury | May 11, 2015
Clinical News

TransCon treprostinil: Phase I data

...A Phase I trial showed that single ascending doses of TransCon treprostinil led to treatment-related injection site...
...issues that Ascendis said did not meet the criteria defined in the target product profile. TransCon treprostinil...
...mitigate current limitations have been addressed.” Ascendis Pharma A/S (NASDAQ:ASND), Hellerup, Denmark Product: TransCon treprostinil ( ACP-009...
BioCentury | Dec 8, 2014
Finance

Ascending to the market

...in mid-2015. Ascendis said it also expects to announce Phase Ib data by YE15 for ACP-009...
Items per page:
1 - 2 of 2